Diversified Trust Co Increases Position in Boston Scientific Corporation $BSX

Diversified Trust Co lifted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 252.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 20,132 shares of the medical equipment provider’s stock after buying an additional 14,427 shares during the period. Diversified Trust Co’s holdings in Boston Scientific were worth $1,263,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Group LLC purchased a new stake in Boston Scientific in the 4th quarter valued at approximately $28,064,000. Rathbones Group PLC raised its stake in shares of Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after buying an additional 477,680 shares in the last quarter. Tounjian Advisory Partners LLC purchased a new position in shares of Boston Scientific during the 4th quarter worth approximately $1,477,000. Waycross Partners LLC acquired a new stake in shares of Boston Scientific in the 4th quarter valued at approximately $2,384,000. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in shares of Boston Scientific in the 3rd quarter valued at approximately $26,955,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific rose as the broader market dipped, suggesting investors are still willing to buy the shares despite volatility and recent weakness. Boston Scientific (BSX) Gains As Market Dips: What You Should Know
• Positive Sentiment: Piper Sandler maintained an Overweight rating, and even after cutting its price target to $65 from $90, it still implies meaningful upside from current levels. Piper Sandler Maintains Overweight Rating for Boston Scientific (BSX)
• Positive Sentiment: Analyst coverage remains broadly constructive, with reports noting Boston Scientific has an average “Moderate Buy” rating on Wall Street. Boston Scientific Corporation (NYSE:BSX) Receives Average Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Truist reportedly lowered its target price, but the headline alone does not indicate a rating downgrade, so the market impact looks mixed rather than clearly negative. Truist Cuts Boston Scientific (BSX) ’s Target as Doctors Change How They Use Its Heart Device
• Negative Sentiment: Unusual options activity showed a sharp increase in put buying, which can signal that some traders are positioning for downside or hedging risk.
• Negative Sentiment: Jim Cramer’s comments that “this whole cohort is just too hard to own” reinforce a cautious view on the medtech group and may add to investor hesitation. Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own”

Insider Transactions at Boston Scientific

In other Boston Scientific news, Director David C. Habiger acquired 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was acquired at an average cost of $55.92 per share, with a total value of $125,820.00. Following the purchase, the director directly owned 13,878 shares in the company, valued at approximately $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Cheryl Pegus acquired 1,770 shares of the business’s stock in a transaction that occurred on Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, with a total value of $99,987.30. Following the completion of the transaction, the director directly owned 1,770 shares in the company, valued at approximately $99,987.30. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired a total of 9,800 shares of company stock valued at $554,012 in the last ninety days. Corporate insiders own 0.34% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BSX. Stifel Nicolaus set a $75.00 price objective on Boston Scientific in a report on Wednesday, May 27th. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a research report on Thursday, April 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $77.00 price target on shares of Boston Scientific in a research note on Monday, May 18th. Piper Sandler reiterated an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a report on Friday, June 12th. Finally, Zacks Research cut shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a research note on Friday, June 5th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $85.08.

Boston Scientific Trading Up 3.0%

NYSE:BSX opened at $45.65 on Wednesday. Boston Scientific Corporation has a 52-week low of $44.05 and a 52-week high of $109.50. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. The stock has a fifty day simple moving average of $54.04 and a 200-day simple moving average of $72.07. The company has a market capitalization of $67.85 billion, a PE ratio of 19.10, a price-to-earnings-growth ratio of 0.85 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The firm had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period in the prior year, the company earned $0.75 EPS. The firm’s revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts expect that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific announced that its board has approved a share repurchase program on Monday, May 18th that authorizes the company to buyback $5.00 billion in shares. This buyback authorization authorizes the medical equipment provider to buy up to 6.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s management believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.